Cargando…

Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer

OBJECTIVE: The safety and efficacy of robotic-assisted laparoscopic hysterectomy (RALH) compared with conventional total laparoscopic hysterectomy (TLH) for surgical staging of endometrial cancer has not been clearly established. With the commencement of a robotic program at our institution, our obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Cherynne Yuin Mun, Chan, Felix Kwok Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508988/
https://www.ncbi.nlm.nih.gov/pubmed/32995747
http://dx.doi.org/10.1016/j.eurox.2020.100116
_version_ 1783585508828381184
author Johansson, Cherynne Yuin Mun
Chan, Felix Kwok Hee
author_facet Johansson, Cherynne Yuin Mun
Chan, Felix Kwok Hee
author_sort Johansson, Cherynne Yuin Mun
collection PubMed
description OBJECTIVE: The safety and efficacy of robotic-assisted laparoscopic hysterectomy (RALH) compared with conventional total laparoscopic hysterectomy (TLH) for surgical staging of endometrial cancer has not been clearly established. With the commencement of a robotic program at our institution, our objective was to evaluate and compare the surgical outcomes of RALH with TLH for endometrial cancer. METHODS: A retrospective cohort study was performed on 39 patients who underwent RALH and 41 patients who underwent TLH for endometrial cancer at a tertiary care academic institution. RESULTS: In the setting of endometrial cancer RALH is significantly longer to perform than TLH (mean operating time 133 min vs 107 min, p = 0.0001). There is higher estimated blood loss in TLH cases than RALH cases (78 mL vs 22 mL, p = 0.015). Women who underwent RALH had a shorter length of stay (1.3 days vs 1.8 days, p = 0.006) than TLH patients, and six cases (15 %) of the RALH group were discharged on the same day of surgery. There were no differences between the RALH and TLH groups in intraoperative or postoperative complications and there were no conversions to laparotomy. CONCLUSION: RALH is safe and feasible for the treatment of endometrial cancer, with low morbidity, less blood loss and shorter length of stay than TLH. RALH is associated with longer mean operating times than TLH and this may improve with enlisting a consistent experienced team. Prospective randomised studies which include analysis of quality of life measures and long-term outcomes are required to further establish the role of RALH in the surgical staging of endometrial cancer.
format Online
Article
Text
id pubmed-7508988
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75089882020-09-28 Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer Johansson, Cherynne Yuin Mun Chan, Felix Kwok Hee Eur J Obstet Gynecol Reprod Biol X Gynaecology: Oncology OBJECTIVE: The safety and efficacy of robotic-assisted laparoscopic hysterectomy (RALH) compared with conventional total laparoscopic hysterectomy (TLH) for surgical staging of endometrial cancer has not been clearly established. With the commencement of a robotic program at our institution, our objective was to evaluate and compare the surgical outcomes of RALH with TLH for endometrial cancer. METHODS: A retrospective cohort study was performed on 39 patients who underwent RALH and 41 patients who underwent TLH for endometrial cancer at a tertiary care academic institution. RESULTS: In the setting of endometrial cancer RALH is significantly longer to perform than TLH (mean operating time 133 min vs 107 min, p = 0.0001). There is higher estimated blood loss in TLH cases than RALH cases (78 mL vs 22 mL, p = 0.015). Women who underwent RALH had a shorter length of stay (1.3 days vs 1.8 days, p = 0.006) than TLH patients, and six cases (15 %) of the RALH group were discharged on the same day of surgery. There were no differences between the RALH and TLH groups in intraoperative or postoperative complications and there were no conversions to laparotomy. CONCLUSION: RALH is safe and feasible for the treatment of endometrial cancer, with low morbidity, less blood loss and shorter length of stay than TLH. RALH is associated with longer mean operating times than TLH and this may improve with enlisting a consistent experienced team. Prospective randomised studies which include analysis of quality of life measures and long-term outcomes are required to further establish the role of RALH in the surgical staging of endometrial cancer. Elsevier 2020-09-06 /pmc/articles/PMC7508988/ /pubmed/32995747 http://dx.doi.org/10.1016/j.eurox.2020.100116 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Gynaecology: Oncology
Johansson, Cherynne Yuin Mun
Chan, Felix Kwok Hee
Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title_full Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title_fullStr Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title_full_unstemmed Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title_short Robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
title_sort robotic-assisted versus conventional laparoscopic hysterectomy for endometrial cancer
topic Gynaecology: Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508988/
https://www.ncbi.nlm.nih.gov/pubmed/32995747
http://dx.doi.org/10.1016/j.eurox.2020.100116
work_keys_str_mv AT johanssoncherynneyuinmun roboticassistedversusconventionallaparoscopichysterectomyforendometrialcancer
AT chanfelixkwokhee roboticassistedversusconventionallaparoscopichysterectomyforendometrialcancer